The diagnosis of cancer is quite fun. But the ability of cancer cells to hide in the body after first treatment is especially trivial. And yet unknown patients still have residual illnesses.
Even some cancer cells that survive can develop at the moment, depending on the original site – milk or colon, for example – to form tumors on other parts of the body. Since the new tumor has grown enough to appear in CT scan, the cancer may not be cured.
When cancer patients seek treatment, fluid from early therapy such as radiation can cause tumors of new and old tumors. And traditional biopsy, a sample of pathological tissue that examines the microscope to explain the signs of cancer, can be difficult to obtain from internal organs such as the lungs.
For all these reasons, physicians have high expectations for technology still in the adult age is a liquid biopsy, which seeks cancer in the body fluids. Can identify cancer patients who are infected after primary care and effective therapeutic help for these people.
Liquid biopsies are a result of genetic research, which causes a strong understanding of DNA cancer. The doctor now knows that a tumor has its own molecular model.
Liquid biopsies can detect typical cell DNA that tumors release body fluids, and quickly. This is often more perceptive than CT. The blood is the preferred medium for current liquid biopsy, although eventually other fluids such as urine and saliva can be played for some types of cancer.
But each clinic can take blood samples, and cancerous dna reliably migrates to the blood, sometimes as a fragment, which is also sufficient for many fluid biopsy tests to read.
Geoffrey Oxnard, a specialist oncologist at lung cancer at the Dana-Farber Cancer Institute in Boston, is working on liquid biopsy in practice. “We can see the evidence of cancer genome in the DNA of patient fluctuations, and we have a more sensitive way to find a low cancer rate,” says Oxnard.
The key challenge with technology is the development of tests that are quite sensitive to detect the low concentration of DNA dying cancer that floats in millions of blood cells.
“Even with patience with stage IV cancer, tests still do not see cancer 20 to 30% of the time,” Oxnard says. Therefore, if the liquid biopsy test returns negative, the physician should continue to use biopsy standards for the patient.
But fluid biopsies also point to a more acceptable treatment for some lung cancer patients. “If a patient with IV lung cancer does not have specific symptoms in the [specific], it can get effective oral therapy with some side effects and dramatic responses,” says Oxnard. The alternative is chemotherapy, which can be less effective and have side effects.
In the clinical context, fluid biopsy tests designed to detect one or two genes can now count hundreds of dollars; Larger panels, with larger genes, can generate thousands of dollars.
Detection of the disease
Liquid biopsy will then bring technology to identify patients who have cure early cancer of certain types and who appear treated by CT scan, but still have remaining illnesses.
Different types may give the patient a second chance, said Ben Ho Park, a researcher and doctor at the Comprehensive Cancer Center Sidney Kimmel at the Johns Hopkins Medical School, Baltimore. Because there is no reliable way to inform those who still have microscopic cancer cells in the body and who do not, standard care now often only cure every person with follow-up therapies.
Researchers find that ultimately the fluid biopsy tests will identify the people with cancer, to prevent unnecessary illness and to treat more effective treatments for those who need it.
Liquid biopsy (Click to expand)
Cancer can go to the bloodstream, like a single cell or free DNA fragment. In the future, fluid biopsy can give an example